Determination of isoprostanes in urine samples from Alzheimer patients using porous graphitic carbon liquid chromatography–tandem mass spectrometry

This publication has 21 references indexed in Scilit:

• Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications
  Trends in Pharmacological Sciences, 2002
• Isoprostanes, Novel Markers of Oxidative Injury, Help Understanding the Pathogenesis of Neurodegenerative Diseases
  Neurochemical Research, 2000
• The Role of Oxidative Stress in Alzheimer Disease
  Archives of Neurology, 1999
• Isoprostanes as Markers of Lipid Peroxidation in Atherosclerosis
  Published by Springer Nature ,1999
• Altered plasma antioxidant status in subjects with Alzheimer's disease and vascular dementia
  International Journal of Geriatric Psychiatry, 1998
• Amyloid β-peptide stimulates nitric oxide production in astrocytes through an NFκB-dependent mechanism
  Proceedings of the National Academy of Sciences, 1998
• Mass spectrometric analysis of four regioisomers of F₂-isoprostanes formed by free radical oxidation of arachidonic acid
  Journal of the American Society for Mass Spectrometry, 1996
• Aging, energy, and oxidative stress in neurodegenerative diseases
  Annals of Neurology, 1995
• Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids.
  Proceedings of the National Academy of Sciences, 1992
• A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism.
  Proceedings of the National Academy of Sciences, 1990